Comparison of 2 cell-based phosphoprotein assays to support Screening and development of an ALK inhibitor

Journal of Biomolecular Screening

Volumn 16, Issue 2, 2011, Pages 164-173

  Drew, Allison E ^a   Al Assaad, Samer ^a   Yu, Violeta ^a   Andrews, Paul ^a   Merkel, Patricia ^a   Szilvassy, Stephen ^a   Emkey, Renee ^a   Lewis, Richard ^a   Brake, Rachael L ^a  

^a AMGEN INC   (United States)

Author keywords

ALK; AlphaScreen ; cell based assays; phosflow

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANAPLASTIC LYMPHOMA KINASE; PHOSPHOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; BIOASSAY; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; INTERMETHOD COMPARISON; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION;

BIOLOGICAL ASSAY; CELL LINE; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; PHOSPHOPROTEINS; PIPERIDINES; PROTEIN-TYROSINE KINASES; PYRIDINES;

EID: 79951988430     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110394657     Document Type: Article

References (35)

1. Yu L-R., Issaq JH, Veenstra DT: Phosphoproteomics for the discovery of kinases as cancer biomarkers and drug targets. Proteomics Clin Appl 2007 ; 1: 1042-1067.
2. Yan JX, Packer NH, Gooley AA, Williams KL: Protein phosphorylation: technologies for the identification of phosphoamino acids. J Chromatogr A 1998 ; 808: 23-41. (Pubitemid 28273216)
3. Chiang GG, Abraham RT: Determination of the catalytic activities of mTOR and other members of the phosphoinositide-3-kinase-related kinase family. Methods Mol Biol 2004 ; 281: 125-141.
4. Blaydes JP, Vojtesek B., Bloomberg GB, Hupp TR: The development and use of phospho-specific antibodies to study protein phosphorylation. Methods Mol Biol 2000 ; 99: 177-189.
5. Kaufmann H., Bailey JE, Fussenegger M.: Use of antibodies for detection of phosphorylated proteins separated by two-dimensional gel electrophoresis. Proteomics 2001 ; 1: 194-199. (Pubitemid 33586715)
6. Mandell JW: Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 2003 ; 163: 1687-1698. (Pubitemid 37309997)
7. Gernez Y., Herzenberg LA, Herzenberg LA, Tirouvanziam R.: Phospho-FACS: a powerful tool for exploring intracellular transduction cascades [in French]. Rev Mal Respir 2007 ; 24: 955-964. (Pubitemid 350125330)
8. Eglen RM, Reisine T., Roby P., Rouleau N., Illy C., Bosse R.,, et al. The use of AlphaScreen technology in HTS: current status. Curr Chem Genomics 2008 ; 1: 2-10.
9. Forrer P., Tamaskovic R., Jaussi R.: Enzyme-linked immunosorbent assay for measurement of JNK, ERK, and p38 kinase activities. Biol Chem 1998 ; 379: 1101-1111. (Pubitemid 28456822)
10. Warner G., Illy C., Pedro L., Roby P., Bosse R.: AlphaScreen kinase HTS platforms. Curr Med Chem 2004 ; 11: 721-730.
11. Guenat S., Rouleau N., Bielmann C., Bedard J., Maurer F., Allaman-Pillet N.,, et al. Homogeneous and nonradioactive high-throughput screening platform for the characterization of kinase inhibitors in cell lysates. J Biomol Screen 2006 ; 11: 1015-1026. (Pubitemid 44847156)
12. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL,, et al. Fusion of a kinase gene ALK to a nucleolar protein gene NPM in non-Hodgkin's lymphoma. Science 1994 ; 263: 1281-1284. (Pubitemid 24107549)
13. Bischof D., Pulford K., Mason DY, Morris SW: Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPManaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997 ; 17: 2312-2325. (Pubitemid 27133318)
14. Pulford K., Morris SW, Turturro F.: Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004 ; 199: 330-358. (Pubitemid 38580430)
15. Lamant L., Pulford K., Bischof D., Morris SW, Mason DY, Delsol G.,, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000 ; 156: 1711-1721. (Pubitemid 30646709)
16. Lin E., Li L., Guan Y., Soriano R., Rivers CS, Mohan S.,, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009 ; 7: 1466-1476.
17. Soda M., Choi YL, Enomoto M., Takada S., Yamashita Y., Ishikawa S.,, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007 ; 448: 561-566. (Pubitemid 47206930)
18. Bai RY, Dieter P., Peschel C., Morris SW, Duyster J.: Nucleophosminanaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 1998 ; 18: 6951-6961. (Pubitemid 28533016)
19. Christensen JG, Zou HY, Arango ME, Li Q., Lee JH, McDonnell SR,, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007 ; 6: 3314-3322.
20. Galkin AV, Melnick JS, Kim S., Hood TL, Li N., Li L.,, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A 2007 ; 104: 270-275. (Pubitemid 46068021)
21. Wan W., Albom MS, Lu L., Quail MR, Becknell NC, Weinberg LR,, et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 2006 ; 107: 1617-1623. (Pubitemid 43242400)
22. Zamo A., Chiarle R., Piva R., Howes J., Fan Y., Chilosi M.,, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002 ; 21: 1038-1047. (Pubitemid 34174516)
23. Joseph RE, Min L., Andreotti AH: The linker between SH2 and kinase domains positively regulates catalysis of the Tec family kinases. Biochemistry 2007 ; 46: 5455-5462. (Pubitemid 46717269)
24. Beckwith M., Longo DL, O'Connell CD, Moratz CM, Urba WJ: Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst 1990 ; 82: 501-509. (Pubitemid 20108054)
25. Fischer P., Nacheva E., Mason DY, Sherrington PD, Hoyle C., Hayhoe FG,, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 1988 ; 72: 234-240.
26. Morgan R., Smith SD, Hecht BK, Christy V., Mellentin JD, Warnke R.,, et al. Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)(p23;q35) common to malignancies with features of so-called malignant histiocytosis. Blood 1989 ; 73: 2155-2164. (Pubitemid 19179549)
27. Fomenko I., Durst M., Balaban D.: Robust regression for high throughput drug screening. Comput Methods Programs Biomed 2006 ; 82: 31-37.
28. Slupianek A., Nieborowska-Skorska M., Hoser G., Morrione A., Majewski M., Xue L.,, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001 ; 61: 2194-2199. (Pubitemid 32692047)
29. Binder C., Lafayette A., Archibeque I., Sun Y., Plewa C., Sinclair A.,, et al. Optimization and utilization of the SureFire phospho-STAT5 assay for a cell-based screening campaign. Assay Drug Dev Technol 2008 ; 6: 27-37. (Pubitemid 351380169)
30. Wellmann A., Doseeva V., Butscher W., Raffeld M., Fukushima P., Stetler-Stevenson M.,, et al. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts. Faseb J 1997 ; 11: 965-972. (Pubitemid 27425898)
31. Varker KA, Kondadasula SV, Go MR, Lesinski GB, Ghosh-Berkebile R., Lehman A.,, et al. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin Cancer Res 2006 ; 12: 5850-5858. (Pubitemid 44629618)
32. Cessna MH, Zhou H., Sanger WG, Perkins SL, Tripp S., Pickering D.,, et al. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol 2002 ; 15: 931-938.
33. Dirks WG, Fahnrich S., Lis Y., Becker E., MacLeod RA, Drexler HG: Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer 2002 ; 100: 49-56. (Pubitemid 34602064)
34. Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., de Pontual L., Combaret V.,, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008 ; 455: 967-970.
35. Koivunen JP, Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes AJ,, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008 ; 14: 4275-4283.